ArticleFrontiers in artificial intelligence2026
Utilising speech-derived biomarkers to detect Alzheimer's disease with BERT-based language models: a machine learning study.
Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early diagnosis is critical for effective management of Alzheimer's disease (AD). While prior studies have shown that speech features can be indicative of AD, most existing work consolidates multiple biomarkers, making it difficult to isolate the contribution of individual features. Objective: This study systematically isolates individual speech biomarkers to quantify their distinct contributions to AD classification performance of language models (LMs) and determine whether targeted biomarker selection improves over consolidated feature sets. Methods: We processed speech transcriptions from DementiaBank to surface discriminatory speech biomarkers-verbal pauses, disfluencies, and unintelligible words. We then fine-tuned and evaluated lightweight LMs (BERT, AlBERT, and DistilBERT) on these biomarker-conditioned transcripts for automatic AD classification. Results: Pauses emerged as the most discriminatory speech biomarker (F1 = 0.8326), significantly outperforming the No-biomarker baseline and other biomarkers. Combining all biomarkers degraded performance relative to pauses alone on average across models, though the effect was model-dependent: BERT's All-biomarkers condition exceeded its own No-biomarker baseline, suggesting that feature combination benefits higher-capacity models. BERT yielded the best performance (F1 = 0.8154) across conditions. Conclusions: Selective use of speech biomarkers such as pauses can meaningfully improve AD detection with lightweight LMs, suggesting that targeted biomarker selection may offer a more interpretable and clinically actionable path than broad feature consolidation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.